CATEGORY: METABOLIC & BLOOD SUGAR
A finger-prick reading is a snapshot: one number, one moment, usually before breakfast. A sensor worn on the arm records the whole film. In a 26-week trial of adults with type 2 diabetes who don’t use insulin, that film changed the ending.1 People given a continuous glucose monitor saw their HbA1c, the blood test that reflects average blood sugar over about three months, fall from 8.8% to 7.2%. With routine finger-stick care it fell to 8.0%. That’s a 0.9-point gap, and in diabetes care a full point is a lot.
Twenty-two clinics, one computer-made split
This wasn’t a specialty-clinic experiment. Researchers enrolled 283 adults at 22 ordinary primary care practices across the United States, all with HbA1c readings of 7.5% or higher and none using insulin. A computer sorted them: 145 wore the sensor, 138 kept checking with a standard glucose meter. Nobody picked their own group. Both groups kept their usual medications and got the same diet and exercise advice, so the sensor itself was the difference being tested. Dexcom, which makes the device, funded the study.
Five more hours a day in the healthy range
Sensor wearers spent 62% of the day with glucose in the target range, against 41% with routine care. That works out to roughly five extra hours every day, and the separation showed up within the first week. By the end, 46% of the sensor group had brought HbA1c under 7%, close to twice the share in the comparison group. The benefit held across ages, incomes, and medication types, including people on GLP-1 drugs. And they kept wearing it: 97% were still using the sensor at 26 weeks.
What six months can’t settle
Seeing a number respond to a meal or a walk, in real time, seems to change behavior in ways a morning snapshot doesn’t. What this trial can’t say is whether the improvement lasts. A six-month extension is still running, and the participants started with fairly high readings, so people whose diabetes is already well controlled might see less. The company’s funding is worth keeping in view too, though the trial was run with an independent coordinating center and published in a peer-reviewed journal.
Key Takeaways
- Adults with type 2 diabetes not using insulin lowered HbA1c from 8.8% to 7.2% over 26 weeks with a continuous glucose monitor, versus 8.0% with routine finger-stick care.
- Sensor users spent about five more hours a day in the target glucose range, a difference visible within the first week.
- The trial was funded by the device’s maker and lasted six months, so durability beyond that is still an open question.
References
- Oser T, Beck RW, Martens T, et al. Continuous Glucose Monitoring in Non–Insulin-Treated Type 2 Diabetes. New England Journal of Medicine. 2026; DOI 10.1056/NEJMoa2608571. link